CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
August 01, 2023 16:15 ET
|
CytoSorbents
Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points...
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
July 26, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
July 19, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
June 15, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Royalty Rates for the Medical Devices Industry: Negotiating Licenses, Valuing Medical Technology and Establishing Patent Infringement Damages
May 04, 2023 07:48 ET
|
Research and Markets
Dublin, May 04, 2023 (GLOBE NEWSWIRE) -- The "Royalty Rates for Medical Devices 2022" report has been added to ResearchAndMarkets.com's offering.Royalty Rates for Medical Devices & Diagnostics...
CytoSorbents Reports First Quarter 2023 Results
May 02, 2023 16:15 ET
|
CytoSorbents
PRINCETON, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents to Report First Quarter 2023 Operating and Financial Results
April 26, 2023 07:00 ET
|
CytoSorbents
MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...
CytoSorbents Announces Board Chairman Al W. Kraus To Retire
April 19, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
March 29, 2023 08:30 ET
|
CytoSorbents
PRINCETON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
March 14, 2023 07:00 ET
|
CytoSorbents
PRINCETON, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...